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ABSTRACT
Endoplasmic reticulum (ER) chaperone Prolyl 4-hydroxylase, beta polypeptide 
(P4HB) has previously been identified as a novel target for chemoresistance in 
glioblastoma multiforme (GBM). Yet its functional roles in glioma carcinogenesis 
remain elusive. In clinical analysis using human glioma specimens and Gene 
Expression Omnibus (GEO) profiles, we found that aberrant expression of P4HB 
was correlated with high-grade malignancy and an angiogenic phenotype in glioma. 
Furthermore, P4HB upregulation conferred malignant characteristics including 
proliferation, invasion, migration and angiogenesis in vitro, and increased tumor 
growth in vivo via the mitogen-activated protein kinase (MAPK) signaling pathway. 
Pathway analysis suggested genetic and pharmacologic inhibition of P4HB suppressed 
MAPK expression and its downstream targets were involved in angiogenesis and 
invasion. This is the first study that demonstrates the oncogenic roles of P4HB and 
its underlying mechanism in glioma. Since tumor invasion and Vascularisation are 
typical hallmarks in malignant glioma, our findings uncover a promising anti-glioma 
mechanism through P4HB-mediated retardation of MAPK signal transduction.
INTRODUCTION
Glioblastoma multiforme (GBM) is characterised 
by its highly infiltrative and proliferative invasion of 
surrounding tissues, which makes it one of the most lethal 
types of primary brain tumours [1, 2]. Despite multimodal 
treatments involving surgical resection, chemotherapy and 
radiotherapy, patients with GBM have life expectancies 
of only around 15 months after diagnosis [3]. One 
major reason for treatment failure is GBM’s aggressive 
behaviour that invade surrounding tissues, which 
precludes complete tumour excision [4, 5]. Exploiting 
the signaling mechanisms that drive tumour progression 
and invasion could be important for the development of 
therapeutics for this deadly disease.
Endoplasmic reticulum (ER) is the major site for 
protein synthesis, and the ER chaperone functions to 
ensure proper folding of newly synthesized proteins. 
With the increment of protein synthesis in proliferating 
cancer cells, the activities of ER chaperones experience 
high demand that might lead to the activation of unfolded 
protein response (UPR) in cancer cells [6, 7]. While this 
class of proteins was traditionally thought to be primarily 
responsible for protein folding and post-translational 
modification within the ER, they are now also found to be 
critical in regulating proliferation, apoptosis and immunity 
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[6, 8]. Moreover, due to the high interconnectivity of the 
ER with other cellular compartments, the functions of ER 
chaperones may also extend beyond the ER by regulating 
pro-oncogenic and pro-survival signals [9, 10]. Therefore, 
perturbation of ER homeostasis could have critical roles in 
Tumourigenesis, and targeting ER chaperones represents a 
novel direction for developing anti-tumor therapy.
Prolyl 4-hydroxylase, beta polypeptide (P4HB) 
is one of the major chaperone proteins [11]. Like other 
ER chaperones, P4HB, is also located on the cell surface, 
with activities distinct from those in the ER [12, 13]. 
These findings expanded the paradigm of P4HB functions, 
and implied a high versatility of this protein in different 
biological processes. Elevated levels of P4HB may 
confer tolerance against extracellular stresses such as 
hypoxia and ischemia [14]. Its expression following serial 
transplantations of clinical glioblastoma xenografts in the 
brains of immunodeficient rats also showed correlations 
with invasive properties [15]. 
Recently, we showed that upregulation of P4HB 
was associated with temozolomide (TMZ) resistance in 
malignant glioma, and that its inhibition may sensitize 
chemoresistant glioma to TMZ treatment [16]. This 
study aimed at delineating the oncogenic role of P4HB in 
malignant glioma. Our work provided novel findings that 
aberrant expression of P4HB promotes tumour invasion, 
angiogenesis and growth via the MAPK signaling 
pathways. These multifunctional roles implicate its clinical 
significance in cancer. Targeting P4HB with consequential 
blockage of these pathways may provide an alternative 
treatment approach for GBM.
RESULTS
Upregulated P4HB expression is associated with 
high-grade human glioma
We first assessed cytoplasmic P4HB expression 
in 64 human glioma specimens based on the staining 
intensities and percentage of positively stained cells. 
Levels of intensity varied among different cancer grades, 
in that P4HB was detectable in 30/48 (62.5%) high-grade, 
but only 5/16 (31.2%) in low-grade gliomas. Only 12.6% 
of low-grade glioma cases demonstrated more than 25% 
of P4HB-stained cells, which was around 30% relative to 
high-grade glioma (47.9% cases), suggesting that P4HB 
expression was correlated with glioma malignancy grades 
(Figure 1A). High P4HB expression in high grade gliomas 
was further validated by western blot and end-point PCR 
analysis at the protein and mRNA levels (Figure 1B). 
P4HB expression is correlated with increased 
angiogenesis
In addition to clinical grading (p = 0.013), P4HB 
expression in malignant glioma was also found to be 
significantly correlated with angiogenesis as indicated by 
CD31 expression (p = 0.009), and a positive association 
with VEGF (p = 0.07) (Table 1). Microvessels (arterioles, 
venules, and capillaries) densities and VEGF staining 
intensities were significantly stronger in high-grade (high 
P4HB expression) when compared to the low-grade 
glioma (low P4HB expression) (Figure 2A). Distinctive 
Figure 1: Upregulation of P4HB is associated with high grade glioma. (A) P4HB immunostaining was assessed on a patient 
set of 64 cases. Scoring system was calculated based on intensity of staining (none, weak, moderate and strong; top) and percentage 
of positively stained cells (< 10%, 10%–25% 26%–50%, 51%–75% and > 75%; bottom) in low-grade glioma (LGG) and high-grade 
glioma (HGG) specimens. (B) Representative images demonstrated P4HB protein (upper panel) and gene expression (lower panel) in 
low-grade and high-grade glioma specimens as demonstrated by western blotting and RT-PCR, respectively. β-Actin was used as an 
internal loading control.
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vessel staining patterns, revealed by CD31 staining, were 
observed in a grade-dependent manner with differential 
P4HB expressions. In low-grade glioma with low P4HB 
expression, microvessels were predominantly pericyte-
liked with a capillary phenotype, whereas in high-
grade glioma there was hypervascularity with enlarged, 
branched and disorganized vessel structures. Microvessel 
density (MVD) correlated positively with P4HB in 
both low-grade (p = 0.003) and high-grade gliomas 
(p = 0.0001) (Figure 2B). 
Differential gene expression and biological 
processes associated with P4HB gene expression 
To interrogate the potential mechanisms underlying 
P4HB’s action in the present context, we studied the 
gene expression profiles of 73 patient-derived tissues 
obtained from a publicly available database GSE16011. 
Hierarchical clustering graphically displayed distinct 
differential gene expression patterns between low- 
and high- P4HB groups (Figure 3A). A total of 2227 
differentially expressed genes were identified, of which 
756 were showed two-fold or more differences. 
Gene ontology (GO) enrichment analysis confirmed 
that most up-regulated genes were featured with aspect 
to blood vessel, vasculature and tissue development. 
Others were involved in cell adhesion, extracellular 
matrix organization and wound healing (Figure 3B). The 
findings suggested that P4HB may regulate a wide range 
of gene functions but predominantly in angiogenesis 
and Tumour regulation. Using GeneSpring™, we have 
identified several canonical signaling pathways that 
are significantly correlated with high P4HB expression 
(p < 0.001) (Supplementary Table 1). Of interest is 
the involvement of MAPK signaling pathway together 
with focal adhesion and angiogenesis, which based on 
the degrees of correlation, our previous findings and 
literature reviews, were subject to further investigations 
in this study. 
Involvement of MAPK signaling in P4HB-
dependent oncogenic effects
To study the role of MAPK, D54 and U87 cells were 
treated with increasing concentrations (0, 250 and 500 μM) 
of bacitracin (BAC), a P4HB inhibitor. A dose-dependent 
inhibition of MAPK phosphorylation was observed 
after 24 hour of treatment (Figure 4A). Treatment with 
quercetin-3-rutinoside (Q3R), another potent selective 
inhibitor of P4HB, at increasing concentrations (0, 25, 
50, 100μΜ) for 48 hours similarly suppressed MAPK 
phosphorylation in D54, U87 and U251 cells (Figure 4B). 
The findings suggested that P4HB-dependent oncogenic 
activities are associated with MAPK signaling. 
Table 1: Correlation between P4HB protein expression and clinical/angiogenic variables
Variables No. of cases(n, %)
P4HB protein expression
P value
Low (n, %) High (n, %)
Gender
 Male 37 (57.8) 23 (62.2) 14 (37.8) 0.275
 Female 27 (42.2) 21 (77.8) 6 (22.2)
Age
 < 49.2 32 (50.0) 26 (81.3) 6 (18.8) 0.058
 > 49.2 32 (50.0) 18 (56.3) 14 (43.8)
Grading
 Low grade 16 (25.0) 15 (93.8) 1 (6.3) 0.013†
 High grade 48 (75.0) 29 (60.4) 19 (39.6)
MGMTϗ
 Unmethylated 21 (47.7) 13 (61.9) 8(38.1) 0.752
 Methylated 23 (52.3) 16 (69.6) 7 (30.4)
VEGFϗ
 Low 23 (41.1) 14 (60.9) 9 (39.1) 0.070
 High 33 (58.9) 12 (36.4) 21 (63.6)
CD31ϗ
 Low 24 (42.9) 16 (66.7) 8 (33.3) 0.009†
 High 32 (57.1) 10 (31.3) 22 (68.8)
†Statistically significant
ϗPartial data are not available, and statistics were based on available data.
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Over-expression of P4HB promotes cell 
proliferation, migration, invasion and tube 
formation ability in vitro 
Having found that P4HB expression was associated 
with glioma malignant phenotypes, we then performed 
gain-of-function in vitro assays. Figure 5A illustrates that 
GBM cells with P4HB over-expression were successfully 
established in D54, U87 and U251 cells (D54-P4HB, 
U87-P4HB and U251-P4HB). When compared with the 
vectors controls (D54-Vec, U87-Vec and U251-Vec), 
cells with P4HB over-expression exhibited significantly 
(p < 0.05) higher proliferative rates on MTT assay at 120 
hour (Figure 5B). GBM cells with P4HB over-expression 
also exhibited greater migration abilities at 24 hour than 
vector controls (Figure 5C). A similar trend was observed 
on matrigel invasion assay, with U87-P4HB and U251-
P4HB cells showing greater invasion ability at 24 hours 
when compared to their respective vector controls 
(p < 0.001) (Figure 5D). Angiogenic ability was also 
measured on tube formation assay, parental cells showed 
no branching and tube network formation while GBM 
cells with P4HB over-expression aligned to form branch-
like and net like (Figure 5E).
To further examine the involvement of MAPK 
activities in P4HB-dependent oncogenic effects, MAPK 
phosphorylation was shown to be enhanced in P4HB 
over-expressing U87 and U251 cells (U87 P4HB-1, 
U87 P4HB-2, U251 P4HB-1 and U251 P4HB-2) when 
compared with the vector controls (U87 Vec-Ctrl and 
U251 Vec-Ctrl) (Figure 5F). Suppression of MAPK 
activities by using U0126, at 0, 1, 5, 10 μM for 2 hours 
in P4HB over-expressing U87 and U251 cells (U87 P4HB 
and U251 P4HB) was found to reduce VEGF expression 
without affecting P4HB level (Figure 5G). The invasive and 
angiogenic abilities of U87 P4HB and U251 P4HB cells 
were affected phenotypically after the reduction of MAPK 
activity (Figure 5H and 5I). These findings lend further 
support to the suggestion that the oncogenic activities 
of P4HB are, at least partially, mediated by downstream 
MAPK signaling. 
P4HB enhances Tumourigenicity in orthotopic 
brain tumor grafts
Lastly, we studied the effect of stable P4HB over-
expression (U87 P4HB-1, U87 P4HB-2 and U251 P4HB) 
on tumourigenicity in vivo using an orthotopic xenograft 
model (Figure 6A). At 14 day post-implantation, stable 
P4HB cells (U87 P4HB-1, U87 P4HB-2 and U251 P4HB) 
exhibited significantly greater exponential growth when 
compared with vector control (U87 Vec-Ctrl and U251 
Vec-Ctrl) (p < 0.05) (Figure 6B). At 28 day, the mean 
tumor luciferase radiance (in photons/sec/cm2/sr) for 
U87 implants were 6.62 × 106 (Vec-Ctrl), 1.34 x 108 
(P4HB-1) and 1.28 × 108 (P4HB-2). For U251 implants, 
the luciferase radiances were 1.70 × 106 (Vec-Ctrl) 
and 3.27 × 106 (P4HB) (Figure 6C). Ex vivo histologic 
examination of the tumor grafts by H&E showed increased 
vascularity (Figure 6D) as well as increased P4HB, 
Figure 2: P4HB plays roles in glioma angiogenesis. (A) Immunostaining of high grade glioma (HGG) and low grade glioma (LGG) 
specimens showed that HGG was associated with upregulation of P4HB, CD31 and VEGF expressions. (B) Increase in microvessel density 
(by CD31-positive staining) was associated with upregulation of P4HB (P4HBHigh) in both HGG in both HGG (n = 48; ***p = 0.0001) 
and LGG (n = 16; **p = 0.003). The microvessels in LGG were pericytes-liked with capillary phenotype (black arrows) whereas those in 
HGG showed hypervascularity (HV) of enlarged, branched and disorganized vessel structures (black arrows). Microvessels were found to 
be most abundance in HGG with strong P4HB expression (Scale bars: 50 µm).
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CD31 and CD34 staining in P4HB over-expressing cells 
(Figure 6E). The overall findings suggest that upregulated 
P4HB expression is associated with growth advantage, 
possibly through increased angiogenesis.
DISCUSSION
Neoplastic progression is a multistep process of 
genetic mutations and adaptive responses that can over-
ride growth arrest or senescence controls [17]. Adaptive 
endoplasmic reticulum stress response (ERSR) due to 
chronic ER stress (e.g., caused by hypoxia and glucose 
deprivation) is a common feature in rapidly proliferating 
cancer cells [18], and may protect tumor cells against 
further exogenous insults such as chemotherapeutics 
[19, 20]. ERSR is carried out by chaperones whose 
main functions are to facilitate protein folding and 
the eradication of malformed proteins [21], but recent 
discoveries indicate that chaperones may also affect tumor 
cell growth and signaling [22]. 
Glioma cells are in a constant state of low grade 
ERSR that possibly contributes to their resistance to chemo-
irradiation [21]. The most abundant and well-characterised 
ER chaperone, GRP78 has been identified to be critical 
for tumourigenesis and therapeutic resistance [6, 23], 
exhibiting elevated expression in many cancers, including 
glioma [24]. Cancer cells with constitutively upregulated 
GRP78 could tolerate chemotherapeutic agents through 
the suppression of pro-apoptotic pathways [25]. For 
oncogenesis, GRP78 could induce the activation of AKT 
signaling during leukemogenesis and prostate tumorigenesis 
[26–28]. A conditional heterozygous deletion of GRP78 
may reduce tumour angiogenesis and metastatic growth in 
tumor endothelial cells but not in normal tissue [29]. Other 
chaperones such as GRP 94, calreticulin (CRT) and protein 
disulfide isomerase (PDI) are similarly implicated [30–32]. 
Figure 3: Unique gene expression signature was identified from samples of P4HBLow and P4HBHigh glioma specimens 
(n = 73). (A) By hierarchical clustering analysis, (2-fold cutoff; p ≤ 0.001), a differential gene expression pattern was observed between 
P4HBHigh and P4HBLow groups. (B) Graphical illustration of the most representative gene ontology (GO) identifiers within the GO category 
‘biological processes’, including developmental process, tissue development, invasion purposes, angiogenesis and wound healing. GO 
analysis showed significant associations (p ≤ 0.00001) of genes involved in tumor progression and regulation within the P4HBHigh group 
when compared with the P4HBLow group.
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Figure 4: Involvement of MAPK signaling in P4HB-dependent oncogenic effects. (A) Increasing concentration (0, 250, 500 
μM) of bacitracin, a P4HB inhibitor (24-hour treatment), resulted in inhibition of MAPK phosphorylation in D54 and U87 glioma cells. (B) 
Increasing concentration (0, 25, 50, 100 μM)) of Q3R, another potent selective inhibitor of P4HB (48 hour treatment), suppressed MAPK 
phosphorylation in D54, U87 and U251 glioma lines. β-Actin was used as an internal loading control. 
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Our group has previously identified another ER 
chaperone protein, P4HB, to be associated with TMZ 
resistance in malignant glioma [33]. Down-regulation 
of P4HB enhanced chemosensitivity via the ERSR 
signaling pathway both in vitro and in vivo, implying that 
it is a potential target for chemoresistant GBM [16]. The 
P4HB family also has neuroprotective actions in various 
neurodegenerative diseases and cerebral ischemia [34–36]. 
As such, it is conceivable, though unproven, that high 
P4HB expression in brain tumours may also exert impact 
on disease progression and clinical outcome. Goplen et al. 
were first to identify the role of P4HB in cancer invasion 
but no functional studies or clinical validation were 
reported [15]. Other investigators have also described 
its protective role in post-injury response and anti-tumor 
immunity, its role in glioma tumourigenesis has been 
elusive [37, 38]. The present study is the first to describe 
the oncogenic role of P4HB in GBM and the mechanisms 
underlying its contribution to glioma progression.
MAPK signaling is one of the main EGFR 
downstream pathways that are known to be critical 
for glioma tumourigenesis [39, 40]. MAPK signaling 
are evolutionarily important linkages to the machinery 
that controls fundamental cellular processes such as 
proliferation, migration and apoptosis [41]. Abnormalities 
in MAPK signaling play a critical role in the development 
and progression of cancer [42]. Recently, STL1, the 
co-chaperone stress-in-double protein 1, is reported to 
promote glioma proliferation through MAPK pathways, 
suggests a possible link between MAPK and chaperone 
activities in the development in glioma [43].
Interestingly, we found that up-regulation of P4HB 
was significantly associated with MAPK activation 
signaling and the critical downstream processes of 
angiogenesis and invasion. We also delineated the 
influences of P4HB on the regulations of VEGF. By 
adversely perturbing P4HB in vitro, MAPK and VEGF 
expressions decreased; contrawise, P4HB over-expression 
Figure 5: Transient over-expression of P4HB promoted glioma cell proliferation, migration, invasion and tube 
formation ability in vitro. (A) Western blot analysis showed upregulated expression of P4HB post-transfection. (B) MTT assay was 
performed on cells with transient P4HB over-expression (D54 P4HB, U87 P4HB and U251 P4HB) and empty vector controls (D54 
Vec, U87 Vec and U251 Vec). After 5 days incubation, cells over-expressing P4HB showed higher proliferative rates than controls. (C) 
Migration assay showed greater motility of U87 P4HB and U251 P4HB than their respective vector controls (U87 Vec and U251 Vec). (D) 
Matrigel cell invasion assay similarly showed greater invasiveness in U87 and U251 cells with P4HB over-expression (** p <0.05). (E) 
Angiogenesis, as measured by tube formation ability, was again higher in P4HB overexpressing cells (U87 and U251). (F) Western blot 
analysis revealed that P4HB over-expression was associated with increased MAPK phosphorylation. (G) Suppression of MAPK activities 
by U0126 reduced VEGF expression in P4HB over-expressing cells, while P4HB expression level was unaffected. (H) Representative 
pictures from three independent assays showed decreased cell invasion abilities of U87 P4HB and U251 P4HB cells after treatment with 
U0126. (I) U0126 pretreatment also inhibited tube formation in these cells after 24 h (Magnification: ×200).
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Figure 6: Stable P4HB over-expression was associated with increased tumour growth in vivo in an orthotropic glioma 
model. (A) Western blot analysis confirmed stable P4HB over-expression in transfected cells (U87 P4HB-1 and U87 P4HB-2; U251 
P4HB-1 and U251 P4HB-2). Stable clones of empty vector (D54 Vec-Ctrl and U87 Vec-Ctrl) were used as controls. (B) Quantitative 
BLI was performed for 28 days starting at one week post-transplantation. Representative images demonstrated luciferase activities in 
tumor bearing mice at indicated time-points (Day 7, 14, 21 and 28) post-transplantation. Heat-map scale bar represents photon emission 
(Units = photons/s/cm2/steradian). (C) U87 P4HB-1, U87 P4HB-2 and U251 P4HB cells showed significant increase in bioluminescence 
activities when compared with controls at 28 days post-injection. (*p < 0.05). (D) Coronal section of U87-tumor-bearing mice brain 
showing a well circumscribed tumor within the cerebral hemisphere (dotted line; upper panel). Detection of tumor in ex vivo grafts was 
confirmed using luminescence (top left corner). H&E staining of representative P4HB-over-expressing U87 tumors showed intense tumor 
vessel densities when compared with controls. (Original magnification: ×100; ×400 (insets). (E) Immunohistochemical analysis showed 
expression correlations between P4HB and CD34/CD31 in U87 P4HB-1 and P4HB-2 ex vivo grafts. Representative features are indicated 
by black arrows (Scale bars: 50 μm).
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had the opposite effects. To further verify our findings, we 
suppressed P4HB expression pharmaceutically. BAC is 
widely used as a P4HB inhibitor of uncertain specificity 
of action [44], whereas Q3R has more selective mode 
of action [13]. We observed that both inhibitors could 
suppress MAPK phosphorylation, suggesting that P4HB 
may regulate MAPK signaling. Conversely, inhibiting 
MAPK pathway with U0126 abrogated the induction 
of VEGF, tumor invasion and angiogenesis, without 
alterations in P4HB protein levels. The overall findings 
suggested that MAPK signaling was downstream to P4HB.
MATERIALS AND METHODS
Human glioma specimens and cell lines
A total of 64 specimens (mean age: 49.48 ± 13.80 
years) obtained from 2002 to 2010 were retrieved from 
our institution’s tissue bank and comprised 16 low-
grade gliomas (WHO grade II), 12 anaplastic gliomas 
(WHO grade III) and 36 GBM (WHO grade IV) [2]. The 
diagnosis of malignant glioma was made radiologically 
via magnetic resonance imaging (MRI) before surgery, and 
confirmed histologically by a certified pathologist. The 
study was approved by the Institutional Review Board of 
our institution, and all tissues were collected with signed 
informed consent from patients. 
Human GBM cell lines D54-MG and U87-MG were 
obtained and were described in our previous study [33]. 
U251-MG cell line was obtained from the American Type 
Culture Collection (ATCC; Manassas, VA, USA). D54-
MG was cultured in Dulbecco’s modified Eagle’s medium 
(DMEM)/F12 (1:1), whilst U87-MG and U251-MG 
were cultured in minimum essential medium (MEM)-α 
(GIBCO®; Life Technologies, Inc., Carlsbad, CA, USA) 
at 37oC in 5% CO
2
, 90% relative humidity. All media 
were supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) (GIBCO®), 100 IU/ml penicillin and 100 µg/
ml streptomycin (GIBCO®). 
Immunohistochemical staining 
Details of the procedures used have been described 
in our previous study [16]. Briefly, 4 µm sections were 
deparaffinized in xylene and rehydrated in a descending 
ethanol series. After antigen retrieval in 10 mM sodium 
citrate (pH 6.0), endogenous tissue peroxidase activities 
were quenched by 3% hydrogen peroxide for 20 min 
followed by blocking with 5% normal goat serum 
(Dako, Glostrup, Denmark) for 1 hour. The sections were 
immunostained with rabbit monoclonal anti-P4HB (at 
1:100 dilution; Cell Signalling Technology Inc., Danvers, 
MA, USA), rabbit monoclonal anti-PECAM-1/CD31 
(1:50 dilution; Abcam®, Cambridge, MA, USA), and 
rabbit monoclonal anti-VEGF antibodies (both at 1:200 
dilution; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) at 4oC overnight. After incubation with horseradish 
peroxidase (HRP)-conjugated antibody (Invitrogen-Zymed 
Laboratories, South San Francisco, CA, USA) at 1:200 
dilution, signal was detected using a ready-to-use DAKO 
EnVisionTM+ Kit (Dako). Nonspecific immunoglobulin 
was substituted as negative controls.  
Immunohistochemistry scoring 
To evaluate the degree of marker expression in 
tumour cells, only malignant cells as confirmed by 
our histopathologist were scored. P4HB and VEGF 
expressions were assessed semi-quantitatively by the 
staining intensity (0 = negative, 1 = weak, 2 = moderate, 
3 = strong staining) and percentile quadrants of positive 
cells (0=0%, 1 = 1–25%, 2 = 26–50%, 3=51%–75% and 
4 = 75%) in 10 random high-powered fields [45]. A total 
score varying from 0 to 12 was calculated by multiplying 
the two measurements. Samples were considered positive 
if the score exceeded the median value. 
Microvessel density (MVD) was evaluated after 
CD31 staining [46]. Only stained endothelial cells or 
endothelial cell clusters clearly separated from adjacent 
microvessels, tumour cells, and connective tissue elements 
were considered as single, countable microvessel. All slides 
were initially scanned at low magnification (40× or 100×) 
for the identification of most prominent vascular ‘hot spots’ 
followed by MVD counts on five random 200× microscopic 
fields. The mean value of five counts was recorded and 
the total score was calculated based on the average of 
individual counts made by 2 independent observers. 
Immunoblot
25µg of total protein lysates were separated on 
12% polyacrylamide SDS gels and electroblotted on 
nitrocellulose membranes as previously described [47]. 
Briefly, after blocking with 5% non-fat milk in TBS-T (20 
mM Tris, 137 mM NaCl, 0.1% Tween-20, pH 7.6), the 
membrane was probed with one of the following primary 
antibodies (at 1:1000 dilution) at 4oC overnight: rabbit 
monoclonal antibodies against P4HB, total p44/42 MAP 
kinase (Erk 1/2) (total MAPK), phosphor-p44/42 MAP 
kinase (Erk1/2) (Thr202/Tyr204) (pMAPK), and VEGF (all 
from Cell Signaling Technology Inc.). The membranes were 
washed three times with TBS/T followed by incubation with 
1:10,000 diluted HRP-conjugated secondary antibodies 
(Invitrogen-Zymed Laboratories) at 4oC for 1 hour. Signal 
on blots was developed using ECL detection system (GE 
Biosciences, Buckinghamshire, England).
Semi-quantitative RT-PCR
1 μg of RNA extracts was reverse-transcribed into 
cDNA using the TaqMan reverse transcription reagents 
(Applied Biosystems, CA, USA). PCR amplification was 
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performed in a 20 μLreaction mixture containing 3 μLof 
cDNA template and 200nM of each primer [P4HB or 
beta actin (ACTB)]. ACTB was used as an internal control 
for PCR quality. The primer sequences for P4HB were 
5′-GCTGATGACATCGTGAACTGG-3′ (sense) and 5′- 
TTGGAGAACACGTCACTGTTG-3′ (antisense) and 
ACTB were 5′-CCAACCGCGAGAAGATGA-3′ (sense) 
and 5′-CCAGAGGCGTACAGGGATAG-3′ (antisense). 
The RT-PCR was programmed and started at initial 
incubation at 94°C for 5 min to activate the Taq DNA 
polymerase followed by 35 cycles at 94°C for 45 s, 58°C 
for 45 s, 72°C for 40 s and final extension at 72°C for 
10 min. The RT-PCR assay was repeated twice and PCR 
products were separated by electrophoresis on 2% agarose 
gel and visualized under UV light after ethidium bromide 
staining.
Affymetrix microarray dataset
To interrogate the molecular mechanism underlying 
P4HB’s actions, we studied the gene expression profiles 
of 73 human specimens from Genomic Spatial Event 
(GSE) 16011 at the National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO) 
database (http://www.ncbi.nlm.nih.gov/geo/). These 
included 7 normal controls, 17 World Health Organization 
(WHO) grade II, 29 grade III, and 20 grade IV gliomas. 
The raw CEL files generated from Affymetrix GeneChip 
Human Genome U133 Plus 2.0 Array were Robust Multi-
Array Average (RMA) preprocessed and normalized using 
GeneSpring software version 12.5 (Agilent Technologies, 
Santa Clara, CA, USA). The differential gene expression 
profiles of tissues with low- or high-P4HB expression 
(using the median expression level as cut-off) were 
identified. GO enrichment analysis was performed to 
delineate the predominant functions of up-regulated 
genes (p ≤ 0.00001) under the GO category ‘biological 
processes’.
P4HB over-expression, inhibition and 
subsequent mechanistic in in vitro studies
P4HB human cDNA clone was obtained from 
OriGene Technologies (Rockville, MD, USA). To 
establish P4HB over-expressed cells, full-length P4HB 
cDNA flanked with EcoRI and Not I restriction sites 
was ligated to pcDNA3.1/V5-His©C expression plasmid 
(InvitrogenTM; Life Technologies). pcDNA3.1/V5-His©C-
P4HB and pcDNA3.1/V5-His©C empty vector plasmids 
were transfected into U87-MG and U251-MG cells using 
FuGENE®6 transfection reagent (Roche Diagnostics, 
Indianapolis, IN, USA). For further studies, two stable 
clones with high P4HB expression (P4HB-1 and P4HB-2) 
and one single clone with empty vector as control (Vec-
Ctrl) were selected using neomycin. For in vivo imaging, 
the pLenti-CMV-Puro-LUC lentiviral luciferase vector 
(Addgene, Cambridge, MA, USA) was transfected into 
cells for further selection of stably expressed luciferase 
clones using puromycin. Pharmacologic inhibition of 
P4HB was achieved with quercetin-3-rutinoside (Q3R) 
(Sigma-Aldrich) and bacitricin (BAC) (Sigma-Aldrich). 
MAPK inhibition was achieved by U0126, a small 
molecule inhibitor (Cell signaling Technology Inc).
Intracranial xenograft model
Evaluation of tumorigenicity on parental GBM cells 
and GBM cells with P4HB over-expression was performed 
using orthotopic tumor model based on guidelines 
approved by the Committee on the Use of Live Animal for 
Teaching and Research (CULATR). Immunocompromised 
[athymic nude (nu/nu)] mice at about six weeks of age 
were anesthetized by intra-peritoneal injection of 50 mg/kg 
ketamine/xylazine. Mice were fitted onto a stereotaxic 
device for intracerebral injections (RWD Life Science Co., 
Ltd., ShenZhen, GuangDong Province, China). Briefly, a 
small skin incision was made to expose the bregma suture 
followed by the creation of a small burr hole at anterior-
posterior (AP) = +1 and medial-lateral (ML) = −2.5 from 
bregma by a micromotor drill (Hager & Meisinger GmbH, 
Neuss, Germany). 1 × 106 GBM cells in 5µL of PBS (U87-
Vec-Ctrl, P4HB-1 and P4HB-2; U251-Vec-Ctrl, P4HB) 
were slowly deposited (1µL/min) in the right striatum 
at a depth of −3.5 mm from dura with a 10-µL syringe 
(26-gauge needle; Hamilton Co., Reno, NV, USA). The 
needle was left in place for 1 min and slowly withdrawn in 
3 min followed by closure of the skin incision with sutures. 
Statistical analysis
All statistical analyses were performed using 
PASW Statistics 18.0 (SPSS Inc., Chicago, IL, USA). 
Differentially expressed genes with a fold change ≥ 2 and 
p value ≤ 0.001 were included for Hierarchical Clustering 
Analysis (HCA) [48] and Gene Ontologies (GO) analysis 
for the three categories:- ‘biological process’ (BP), 
‘molecular function’ (MF), and ‘cellular component’ 
(CC) [49]. Pathway analysis in GeneSpring GX software 
was used to identify canonical pathways associated with 
the differentially expressed genes with p value ≤ 0.001. 
Correlation of P4HB expression with different pathological 
grades were analyzed by Pearson’s chi-squared (χ2) test. 
Samples belonging to the P4HBHigh and P4HBLow groups 
were defined based on the median value of the sample 
population. Continuous data were presented as mean ± SD. 
Student’s t-test was used to determine whether a difference 
existed between two groups. One-way ANOVA analysis 
was used for comparison of more than 2 groups. P values 
of less than 0.05 were considered statistically significant.
CONCLUSIONS
This study is the first to describe the oncogenic 
effects of P4HB in glioma and the mechanistic linking of 
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P4HB-mediated MAPK activation in glioma progression, 
invasion and angiogenesis. It provides new knowledge 
on the significance of chaperone proteins dysregulation 
in malignant glioma both clinically and at a molecular 
level. These findings supplement our previous finding that 
inhibition of P4HB may resensitise chemoresistant GBM 
to TMZ. P4HB may be further exploited as a potential 
predictive marker for GBM prognosis and an alternative 
therapeutic approach for GBM and possibility in other 
cancers. Future studies will help to delineation the whole 
picture of P4HB dependent MAPK signaling together with 
their molecular interactions in glioma malignancy.
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